First Citizens BancShares Inc vs Heron Therapeutics Inc — how do they compare? First Citizens BancShares Inc trades at $2,071.11 (market cap $22.94B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: First Citizens BancShares Inc is far larger — about 337.3× Heron Therapeutics Inc's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Heron Therapeutics Inc for 35 Days on average.
| FCNCA | HRTX | |
|---|---|---|
Market Cap | $22.94B | $68.01M |
Volume | 91,668 | 1,891,941 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $1.49 |
52-Week Low | $1.64K | $0.27 |
Typical Hold Time | 29 Days | 35 Days |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $174.75M |
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →